Core Insights - Cidara Therapeutics, Inc. will report its Q3 2025 financial results and operational highlights on November 6, 2025, after U.S. market close [1] - A conference call and webcast will be held at 5:00 PM Eastern Time to discuss the results and business updates [2] Company Overview - Cidara Therapeutics utilizes its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies [3] - The lead DFC candidate, CD388, is designed for universal prevention of seasonal and pandemic influenza with a single dose by inhibiting viral proliferation [3] - CD388 received Fast Track Designation from the FDA in June 2023 and has shown positive results in the Phase 2b NAVIGATE trial in June 2025, with a Phase 3 ANCHOR trial initiated in September 2025 [3]